Clinical Trial Update: A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants [Phase 3]

View source ↗

Summary

A phase 3 trial comparing first-line alectinib to crizotinib in treatment-naive ALK-positive advanced non-small cell lung cancer has completed, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)
• Xalkori (crizotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-03-15